EKOS Corporation, a BTG International group company, located in Bothell, Washington in the United States, has announced the publication of the results of its Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (PE) trial (ULTIMA) in the peer-reviewed journal of the American Heart Association, CIRCULATION. The announcement was made at The International Symposium on Endovascular Therapy (ISET) in Miami, Florida in the United States. The ULTIMA study is the world s first and only prospective randomized controlled clinical trial of patients with submassive PE treated with either standard of care intravenous anticoagulation or the EKOS EkoSonic® Endovascular System and rt-PA (Actilyse®, Boehringer Ingelheim). EKOS unique technology uses ultrasound to accelerate the action of clot-dissolving drugs. Dr. Nils Kucher, Director of the Venous Thromboembolism Research Group at the University Hospital in Bern, Switzerland, is the lead author and principal investigator of the ULTIMA study.
You might think building muscle is a good thing, but that s often not so in the case of blood vessels in adults. In fact, excess smooth muscle is a root problem in many vascular diseases, as it causes arteries to constrict and blood pressure to rise. Now, an in-depth analysis of arterioles in mice with pulmonary hypertension explains how those misplaced smooth muscle cells develop.
Early but not advanced forms of atherosclerotic plaques in the vessel wall disappear when the levels of bad cholesterol are lowered, according to a study in mice from Karolinska Institutet, Sweden. The findings, published in PLoS Genetics, indicate that preventative cholesterol-lowering treatment could prevent more advanced, clinically relevant plaque to develop.
Scientific Statement from American Heart Association details latest evidence for diagnosis and treatment A vascular disease called fibromuscular dysplasia, which can cause high blood pressure, kidney failure, stroke and other symptoms -- mostly in women -- is poorly understood by many healthcare providers, according to a Scientific Statement from the American Heart Association.
Research from The Shiley Center for Orthopaedic Research and Education at Scripps Clinic could change how patients are treated to prevent blood clots after joint replacement surgery. A study recently published as the lead article in the Journal of Bone and Joint Surgery determined that after lower extremity joint replacement surgery a mobile compression device was just as effective as blood thinners in preventing deep vein thrombosis (DVT), but without negative side effects including bleeding complications.
In collaboration with an international team, researchers at Karolinska Institutet in Sweden have developed an antibody, 3F7, which blocks a protein that is active in the coagulation system factor XII. Inhibition of factor XII makes it possible to prevent thrombosis in blood vessels without increasing the risk of bleeding in clinical settings.
CeloNova has announced the US FDA 510(k) clearance expanding the indication for Embozene microspheres to include the treatment of uterine fibroids.
The European Congress of Radiology (ECR), the annual meeting of the European Society of Radiology (ESR) was held 6–10 March, Vienna, Austria.
A retrospective study reports that individuals who underwent embolization of the left gastric artery for gastrointestinal bleeding experienced a 7.9% decrease in body weight, three months after the procedure. Could embolization of the left gastric artery be used in the treatment of obesity?
BSD Medical has reported continued sales momentum by Terumo on the distribution of the MicroThermX Microwave Ablation system. BSD’s exclusive agreement with Terumo covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa.
Cordis has announced receiving the CE mark for its Renlane renal denervation system for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe.
Cordis Corporation announced that it has entered into an agreement with TriReme Medical that grants the company exclusive distribution rights for the Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter.
Endologix has announced the Journal of Vascular Surgery s (JVS) e-publication of the data from the first prospective, multicentre, randomised clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR).
Results from the RELINE trial show that the Viabahn covered stent (Gore) conferred significantly better protection against target lesion revascularisation and had a significantly higher primary patency than percutaneous transluminal angioplasty.
The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology, are the result of the most rigorous investigation on the subject to-date. These exceptional numbers (97%, five-year oncologic efficacy and 6% complication rate) however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos